Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia


      This double-blind study was designed to assess the efficacy and safety of fluvastatin-fenofibrate combination therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol ≥190 mg/dl [4.9 mmol/L], triglycerides ≤350mg/dl [3.9 mmol/l]). After a 10-week placebo and dietary baseline period, 102 patients were randomized to receive micronized fenofibrate 200 mg, fluvastatin 20 mg plus micronized fenofibrate 200 mg, or fluvastatin 40 mg plus micronized fenofibrate 200 mg. At week 16, fenofibrate 200 mg alone lowered LDL cholesterol from baseline by 21% compared with 32% for fluvastatin 20 mg plus fenofibrate 200 mg and 41% for fluvastatin 40 mg plus fenofibrate 200 mg (p <0.001). Triglycerides decreased by 29% with fenofibrate 200 mg alone, 39% with fluvastatin 20 mg plus fenofibrate 200 mg, and 40% with fluvastatin 40 mg plus fenofibrate 200 mg (p <0.05). Safety was assessed by recording adverse events and measuring clinical laboratory parameters. The adverse event profile was similar for the 3 treatment groups. One patient withdrew due to an increase in transaminase levels. No significant increase in creatine phosphokinase levels was observed with combination therapy. In conclusion, the addition of fluvastatin to micronized fenofibrate results in substantial improvement in atherogenic plasma lipids and is well tolerated.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dujovne C.A
        New lipid lowering drugs and new effects of old drugs.
        Curr Opin Lipidol. 1997; 8: 362-368
        • Fruchart J.C
        • Brewer H.B
        • Leitersdorf E
        Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease.
        Am J Cardiol. 1998; 81: 912-917
      1. Prevention of coronary heart disease.
        Nut Metab Cardiovasc Dis. 1992; 2: 113-156
      2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II).
        Circulation. 1994; 89: 1329-1445
        • Brewer H.B
        Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors.
        Atherosclerosis. 1992; 97: S11-S19
        • Tikkanen M.J
        Curr Opin Lipidol. 1996; 7: 385-388
        • Pierce L.R
        • Wysowski D.K
        • Gross T.P
        Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
        JAMA. 1990; 264: 71-75
        • Marais G.E
        • Larson K.K
        Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
        Ann Int Med. 1990; 112: 228-230
        • Feher M.D
        • Foxton J
        • Banks D
        • Lant A.F
        • Wray R
        Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolemia in patients with coronary artery disease.
        Br Heart J. 1995; 74: 14-17
        • Athyros V.G
        • Papageorgiou A.A
        • Hatzikonstandinou H.A
        • Didangelos T.P
        • Carina M.V
        • Kranitsas D.F
        • Kontopoulos A.G
        Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
        Am J Cardiol. 1997; 80: 608-613
        • Ellen R.L.B
        • McPherson R
        Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
        Am J Cardiol. 1998; 81: 60B-65B
        • Deslypere J.P
        The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia.
        Curr Therap Res. 1995; 56: 111-128
        • Langtry H.D
        • Markham A
        Fluvastatin. A review of its use in lipid disorders.
        Drugs. 1999; 57: 583-606
        • Leitersdorf E
        • Muratti E.N
        • Eliav O
        • Meiner V
        • Eisenberg S
        • Dann E.J
        • Sehayek E
        • Peters T.K
        • Stein Y
        Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia.
        Am J Med. 1994; 96: 401-407
        • Eliav O
        • Schurr D
        • Pfister P
        • Friedlander Y
        • Leitersdorf E
        High-dose fluvastatin and bezafibrate combination for heterozygous familial hypercholesterolemia.
        Am J Cardiol. 1995; 76: 76A-79A
        • Balfour J.A
        • McTavish D
        • Heel R.C
        Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
        Drugs. 1990; 40: 260-290
        • Farnier M
        • Bonnefous F
        • Debbas N
        • Irvine A
        Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
        Arch Intern Med. 1994; 154: 441-449
        • Friedewald W.T
        • Levy R.I
        • Frederickson D.S
        Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Shepherd J
        Fibrates and statins in the treatment of hyperlipidemia.
        Eur Heart J. 1995; 16: 5-13
        • Duell P
        • Connor W
        • Illingworth D.R
        Rhabdomyolysis after taking atorvastatin with gemfibrozil.
        Am J Cardiol. 1998; 81: 368-369
        • Pogson G.W
        • Kindred L.H
        • Carper B.G
        Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.
        Am J Cardiol. 1999; 83: 1146
        • Smit J.W.A
        • Jansen G.H
        • de Bruin T.W.A
        • Erkelens D.W
        Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
        Am J Cardiol. 1995; 76: 126A-128A